Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...

Billed as “the year of democracy,” 2024 may ultimately be remembered as the year voters sent incumbents packing. What might ...

A new, presumably more precise or, hopefully, more relevant, pain scale, named the Detroit Interventional Pain Management ...

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Researchers offer a principled way to assess if humans suffer more than other species or if pigs suffer more than chickens; ...

More than 227,000 people died in the December 26, 2004 Indian Ocean tsunami, and experts warn it could happen again.